Position in RPRX
as of Mar 31, 2026
· filed Apr 16, 2026
Position Value
$2,364,249
New position
Shares Held
49,286
first reported quarter
Ownership
0.009%
of shares outstanding
% of Portfolio
0.35%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Stanley-Laman Group, Ltd. holds $15,422,589 across 6 Biotechnology names. RPRX ranks #5 (15.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
155,021 | $3,838,319 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
19,260 | $3,255,325 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
39,306 | $2,951,487 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
68,625 | $2,766,273 | |
| 5 | RPRX |
Royalty Pharma plc
This page
|
49,286 | $2,364,249 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
553 | $246,936 |
All Filings in RPRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,364,249 | 49,286 | Shares | Sole | 2026-04-16 | |
| No filing history on record for this holder in this stock. | ||||||